Unsplash-neuron image_2018-11-30.jpg

Disclosure: Many publications were reviewed and found to be of strong merit. We chose to list only a few of these publications here based on independent review by the Beatty Laboratory and relevance to our work.

Major Scientific Advances in Glioblastoma


FEB, 2019 Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 Feb 11. doi: 10.1038/s41591-018-0337-7. [Epub ahead of print]


DEC, 2018 Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018 Dec 19. doi: 10.1038/s41586-018-0792-9. [Epub ahead of print]

SEP, 2018 Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018 Sep;24(9):1459-1468.

AUG, 2018 Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018 Aug;560(7717):243-247.

JUL, 2018 Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med. 2018 Jul 12;379(2):150-161.

MAY, 2018 Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors. Cancer Cell. 2018 Jul 9;34(1):119-135.e10.

MAY, 2018 AMP kinase promotes glioblastoma bioenergetics and tumour growth. Nat Cell Biol. 2018 Jul;20(7):823-835.

MAY, 2018 An anatomic transcriptional atlas of human glioblastoma. Science. 2018 May 11;360(6389):660-663.

FEB, 2018 Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 2018 Feb 28;10(430).


AUG, 2017 Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-2316.

AUG, 2017 Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell. 2017 Aug 14;32(2):253-267.e5.

JUL, 2017 A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 Jul 19;9(399).

MAR, 2017 Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037.


DEC, 2016 Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016 Dec 29;375(26):2561-9.

DEC, 2016 Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016 Dec 21;8(370):370ra180.

JUL, 2016 Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016 Jul 1;34(19):2206-11.

JUN, 2016 Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2.

MAY, 2016 The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016 May 20;352(6288):aad3018.

MAY, 2016 Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016 May 10;34(14):1611-9.

MAR, 2016 Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med. 2016 Mar 2;8(328):328ra27.

FEB, 2016 Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell. 2016 Feb 8;29(2):201-13.


DEC, 2015 Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15;314(23):2535-43.

DEC, 2015 International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015 Dec 10;33(35):4145-50.

OCT, 2015 Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell. 2015 Oct 12;28(4):441-455.

SEP, 2015 Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14;28(3):318-28.

MAR, 2015 Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366-9.

FEB, 2015 Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18;7(275):275ra22.

FEB, 2015 Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015 Feb;17(2):170-82.


NOV, 2014 Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov;4(11):1299-309.

JUN, 2014 Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014 Jun 20;344(6190):1396-401.

FEB, 2014 Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709-22.

FEB, 2014 A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699-708.


NOV, 2013 Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10;31(32):4085-91.

OCT, 2013 CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19(10):1264-72.

OCT, 2013 The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10;155(2):462-77.

SEP, 2013 Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013 Sep 9;24(3):331-46.

MAR, 2013 Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013 Mar 28;153(1):139-52.


AUG, 2012 Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26.

AUG, 2012 A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012 Aug 23;488(7412):522-6.


FEB, 2011 NFKBIA deletion in glioblastomas. N Engl J Med. 2011 Feb 17;364(7):627-37.

JAN, 2011 Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 Jan 20;29(3):330-6.


DEC, 2010 Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010 Dec 9;468(7325):824-8.

NOV, 2010 Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 1;28(31):4722-9.

JAN, 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19;17(1):98-110.


DEC, 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009 Dec 1;27(34):5743-50.

OCT, 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.

MAY, 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66.

APR, 2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009 Apr 10;324(5924):261-5.

MAR, 2009 Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009 Mar 10;27(8):1275-9.

Feb, 2009 IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73.

FEB, 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5.